Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Anti-B7H3 APDC 3f [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.04% (Day 30)	Positive B7H3 expression (B7H3 +++/++)
Method Description	Both APDCs (10 mg/kg) have been administered to B7H3-positive U251-glioma-tumor-bearing mice; 24hours after treatment, tumors and organs were collected.
In Vivo Model	U251 CDX model
In Vitro Model	Astrocytoma	U-251MG cells		CVCL_0021
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 50)	Positive B7H3 expression (B7H3 +++/++)
Method Description	In the B7H3-positive, slowly growing head and neck squamous cell carcinoma model SCC4, APDC 3 g at a dose of 10 mg/kg given 3 times in a weekly schedule which favorably compared to cisplatin and radiation therapy.
In Vivo Model	SCC4 CDX model
In Vitro Model	Tongue squamous cell carcinoma	SCC-4 cells		CVCL_1684

Anti-B7H3 APDC 3g [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.08% (Day 30)	Positive B7H3 expression (B7H3 +++/++)
Method Description	Both APDCs (10 mg/kg) have been administered to B7H3-positive U251-glioma-tumor-bearing mice; 24hours after treatment, tumors and organs were collected.
In Vivo Model	U251 CDX model
In Vitro Model	Astrocytoma	U-251MG cells		CVCL_0021

References

Ref 1	Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation. Chemistry. 2019 Jun 21;25(35):8208-8213. doi: 10.1002/chem.201900441. Epub 2019 Apr 15.